OVARIAN SEROUS SURFACE PAPILLARY ADENOCARCINOMA
Clinical trials for OVARIAN SEROUS SURFACE PAPILLARY ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN SEROUS SURFACE PAPILLARY ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN SEROUS SURFACE PAPILLARY ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat ovarian cancers?
Disease control OngoingThis study is testing if adding an experimental drug called AZD1775 to a standard chemotherapy (gemcitabine) works better than the chemotherapy alone. It is for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned and stopped responding to platinum-based…
Matched conditions: OVARIAN SEROUS SURFACE PAPILLARY ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
Two-Pronged attack on tough cancers shows promise
Disease control OngoingThis study tested a combination of two drugs, cediranib and olaparib, for people with recurrent ovarian, fallopian tube, peritoneal, or triple-negative breast cancer. The goal was to see if using both drugs together is safe and works better than using olaparib alone to control th…
Matched conditions: OVARIAN SEROUS SURFACE PAPILLARY ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC